Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial

IMPORTANCE: Atabecestat, a nonselective oral β-secretase inhibitor, was evaluated in the EARLY trial for slowing cognitive decline in participants with preclinical Alzheimer disease. Preliminary analyses suggested dose-related cognitive worsening and neuropsychiatric adverse events (AEs). OBJECTIVE:...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Neurol
Main Authors: Sperling, Reisa, Henley, David, Aisen, Paul S., Raman, Rema, Donohue, Michael C., Ernstrom, Karin, Rafii, Michael S., Streffer, Johannes, Shi, Yingqi, Karcher, Keith, Raghavan, Nandini, Tymofyeyev, Yevgen, Bogert, Jennifer, Brashear, H. Robert, Novak, Gerald, Thipphawong, John, Saad, Ziad S., Kolb, Hartmuth, Rofael, Hany, Sanga, Panna, Romano, Gary
Format: Artigo
Language:Inglês
Published: American Medical Association 2021
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7816119/
https://ncbi.nlm.nih.gov/pubmed/33464300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2020.4857
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items